A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006851/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The main aim of this study is to see if giving LDX to children and adolescents aged 6-17
years with ADHD decreases symptoms of ADHD.
提供机构：
Vivli
创建时间：
2021-04-07
